Alzheimer's Disease Diagnostics & Therapeutics Industry Overview
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Alzheimer's Disease Diagnostics & Therapeutics Market Analysis
The Alzheimer's disease diagnostics and therapeutics market is currently valued at USD 6,986.70 million and is expected to be valued at USD 9,639.23 million at the end of the forecast period, registering a growth with CAGR of 5.51% over the forecast period.
The emergence of the COVID-19 pandemic impacted the Alzheimer's disease diagnostics and therapeutics market, as diagnostic and therapeutic procedures worldwide were Alzheimer's due to the decline in visits to hospitals and diagnostic centers because of government regularizations globally in early 2020. For instance, an article published in Brain Sci. in February 2021 stated that patients with dementia were at increased risk of severe disease and death when infected with COVID-19. Thus, as a measure of prevention, there is a decrease in the treatment and diagnostic visits to hospitals and other healthcare facilities. However, as better access to affectedAlzheimer'sr’s diagnostic and therapeutic services is currently compared to the initial pandemic times, the market is expected to regain its growth pace over the studied period.
The major factors driving the growth of the Alzheimer’s disease diagnostics and therapeutics market are the increasing use of biomarkers in Alzheimer's diagnosis and drug development and the rising prevalence of Alzheimer's worldwide. For instance, in September 2022, a report by the WHO stated that about 55 million people around the world are living with dementia, and nearly 10 million cases are reported annually. WHO also said that Alzheimer's is the most common form of dementia and constitutes about 60-70% of the total cases of dementia.
Also, with the growing prevalence of Alzheimer's around the world, government and non-government entities are investing heavily in developing diagnostics and therapeutics for the disease, which may augment the market's growth. For instance, in June 2021, the ADDF Diagnostics Accelerator launched four new research investments to develop digital biomarkers for Alzheimer's diagnosis. Investments like these are further expected to propel the market growth.
Additionally, with the advancement in diagnostic technologies and ongoing research activities in the area, the companies are enhancing their product offering and launching new products coupled with other business expansion initiatives like mergers and acquisitions, strategic collaboration, and new investments into other companies are also expected to complement the growth of the Alzheimer's disease diagnostics and therapeutics market over the forecast period. For instance, in November 2021, Brigham and Women's Hospital in Boston, United States, started a clinical trial to test the safety and efficacy of a new nasal vaccine for Alzheimer's disease. Thus, such therapeutics development leads to better drugs for Alzheimer's treatments, thereby driving the growth of the studied market.
Thus, due to the use of biomarkers, increasing research and development, and advanced diagnostic technologies, the studied market is expected to witness healthy growth over the forecast period. However, high failure rates of clinical studies related to diagnosis and treatment and challenges in early diagnostics of Alzheimer's may impede the market growth over the forecast period.
Alzheimer's Disease Diagnostics & Therapeutics Industry Segments
As per the scope of the report, Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss of memory, thinking and language skills, and behavioral changes. There is a rapid growth in the number of people living with Alzheimer's disease, and only around one in four people with the disease get diagnosed. The Alzheimer's Disease Diagnostics and Therapeutics Market is Segmented by Product (Therapeutics (Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Other Therapeutics) and Diagnostics (Brain Imaging and CSF Test for Alzheimer's Disease)) and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across the major regions globally. The report offers the value (in USD million) for all the above segments.
Alzheimer's Disease Diagnostics & Therapeutics Market Trends
Cholinesterase Inhibitors is Expected to Witness a Significant Growth Over the Forecast Period.
Cholinesterase inhibitors, also known as acetylcholinesterase inhibitors, are a class of therapeutics that stop the normal breakdown of acetylcholine, a neurotransmitter. The cholinesterase inhibitors shut off the action of the enzyme cholinesterase, which is responsible for breaking down acetylcholine neurotransmitters in the body. As cholinesterase inhibitors are found to slightly delay the loss of brain function in people suffering from mild to moderate focus Alzheimers disease, they are widely prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Currently, the major cholinesterase inhibitor drugs available and Alzheimer's use in the market are donepezil, galantamine, rivastigmine, and memantine.
Currently, in the market, cholinesterase inhibitors are the Alzheimer's drugs available for Alzheimer’s because the enzyme cholinesterase is a significant therapeutic primary for Alzheimer's. Hence, the segment is expected to grow over the forecast period as several pharmaceutical companies Alzheimer's developing Alzheimer’s therapeutics based on cholinesterase inhibitors. For instance, in October 2021, Corium, Inc., reported the USFDA has set a PDUFA target actionCorium'sium's new drug application for once-weekly ADLARITY (donepezil transdermal systcommonly it’s a patch formulation of donepezil. This patch treats dementia due to mild, moderate, or severe Alzheimer's disease.
Also, an article published by AGS journal in December 2021 stated that older adults with Alzheimer's disease respond better when treated with cholinesterase inhibitors. Thus, the rising geriatric population with Alzheimer's disease is leading to increasing demand for cholinesterase inhibitors, thereby contributing to the growth of this segment.
Thus, due to the practical results of cholinesterase inhibitors in treating Alzheimer's disease, new product launches and the increasing geriatric population is expected to witness significant growth over the forecast period.
To understand key trends, Download Sample Report
North America is Expected to Witness a Significant Growth Over the Forecast Period.
North America is expected to witness significant growth over the forecast period owing to the high burden of Alzheimer’s disease and the increasing aging population, huge investment in research and development activities, and the launch of new products in the region. For instance, in June 2021, in an interview, the Chief Science Officer of the Alzheimer’s Society of Canada stated that in the upcoming 10 years, it is anticipated that more than one million people in Canada will be living with dementia. This indicates that the increasing prevalence of Alzheimer’s in the North American region is expected to increase the demand for diagnostic and therapeutic products for Alzheimer’s, which may drive market growth over the forecast period.
Also, the growing aging population in the region is expected to increase the burden of Alzheimer’s disease, as the geriatric population is more prone to neurodegenerative diseases like Alzheimer’s as it is an age-associated disease. For instance, in March 2022, the Alzheimer’s Association Report stated that approximately 6.2 million people of age 65 years and more are living with Alzheimer’s-related dementia in the United States, and it is projected that this number will increase to 13.8 million people by 2060.
With the increasing number of research studies related to the diagnosis and management of Alzheimer's disease and high investment in the country over Alzheimer’s by the government and private entities, the market is expected to grow in the United States over the forecast period. For instance, in October 2021, Salk Institute initiated a phase 1 clinical trial of the investigational Alzheimer’s drug CMS121 to evaluate its safety in humans. Thus, such pipeline drugs are leading to the development of better therapeutics for Alzheimer’s disease, thereby driving the growth of the studied market in the region.
Therefore, due to the high burden of Alzheimer’s disease and huge investment in research and development activities, coupled with the launch of new products, the Alzheimer’s disease diagnostics, and therapeutics market is expected to grow over the forecast period in the region.
To understand geography trends, Download Sample Report
Alzheimer's Disease Diagnostics & Therapeutics Market Competitor Analysis
The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several significant players; some of the companies are F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc., Eisai Co. Ltd, Biogen Inc., Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc., Siemens Healthineers, Zydus Cadila, Merz Pharma, Teva Pharmaceutical Industries Ltd., and Adamas Pharmaceuticals Inc.
Alzheimer's Disease Diagnostics & Therapeutics Market Top Players
F. Hoffmann-La Roche
Johnson & Johnson
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Alzheimer's Disease Diagnostics & Therapeutics Market Recent Developments
- In October 2022, Cyclo Therapeutics, Inc. promulgated the commencement of its Phase 2b study of Trappsol Cyclo for the treatment of Alzheimer’s disease, targeting the reduction of amyloid beta and tau. The Phase 2b study received IRB approval.
- In September 2022, Esai Co., Ltd., and Biogen Inc. reported positive topline results from Eisai’s sizeable global Phase 3 confirmatory Clarity AD clinical trial of lecanemab, an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease and mild Alzheimer’s disease.
Alzheimer's Disease Diagnostics & Therapeutics Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Use of Biomarkers in Diagnosis and Drug Development
4.2.2 Large Number of Drugs in Pipeline
4.2.3 Emerging Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 High Failure Rates of Late-stage Drugs
4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
188.8.131.52 Cholinesterase Inhibitors
184.108.40.206 NMDA Receptor Antagonists
220.127.116.11 Other Therapeutics
18.104.22.168 Brain Imaging
22.214.171.124 CFS Test for Alzheimer's Disease
5.2.1 North America
126.96.36.199 United States
188.8.131.52 United Kingdom
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.2.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.2.5 South America
188.8.131.52 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche
6.1.2 Bristol-Myers Squibb
6.1.3 AstraZeneca PLC
6.1.4 Corium Inc.
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc.
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly and Company
6.1.9 Lupin Limited
6.1.10 AbbVie Inc.
6.1.11 Siemens Healthineers
6.1.12 Zydus Cadila
6.1.13 Merz Pharma
6.1.14 Teva Pharmaceutical Industries Ltd
6.1.15 Adamas Pharmaceuticals Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Alzheimer's Disease Diagnostics & Therapeutics Market Research FAQs
What is the study period of this market?
The Alzheimer's Disease Diagnostics and Therapeutics Market market is studied from 2019 - 2027.
What is the growth rate of Alzheimer's Disease Diagnostics and Therapeutics Market ?
The Alzheimer's Disease Diagnostics and Therapeutics Market is growing at a CAGR of 5.51% over the next 5 years.
What is Alzheimer's Disease Diagnostics and Therapeutics Market size in 2019?
The Alzheimer's Disease Diagnostics and Therapeutics Market is valued at 6986 Million USD in 2019.
What is Alzheimer's Disease Diagnostics and Therapeutics Market size in 2027?
The Alzheimer's Disease Diagnostics and Therapeutics Market is valued at 9639 Million USD in 2027.
Which region has highest growth rate in Alzheimer's Disease Diagnostics and Therapeutics Market ?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Alzheimer's Disease Diagnostics and Therapeutics Market ?
North America holds highest share in 2021.
Who are the key players in Alzheimer's Disease Diagnostics and Therapeutics Market ?
F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Johnson & Johnson, Eli Lilly and Company are the major companies operating in Alzheimer's Disease Diagnostics and Therapeutics Market .
Alzheimer's Disease Diagnostics and Therapeutics Industry Reports
In-depth industry statistics and market share insights of the Alzheimer's Disease Diagnostics and Therapeutics Market sector for 2020, 2021, and 2022. The Alzheimer's Disease Diagnostics and Therapeutics Market research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Alzheimer's Disease Diagnostics and Therapeutics Market report PDF.